News & Events about Homology Medicines Inc.
Homology Medicines, Inc. (NASDAQ:FIXX Get Rating) has received a consensus rating of Moderate Buy from the ten brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and six have given a buy ...
PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) on behalf of the Companys long-term investors. Recently an amended securities fraud complaint was filed against Homology on behalf of ...
Globe Newswire
3 months ago
- Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design - BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1...
Globe Newswire
4 months ago
PHILADELPHIA, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) on behalf of the Companys long-term investors. Recently an amended securities fraud complaint was filed against Homology on behalf of ...
Globe Newswire
6 months ago
AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-...